Ignite Creation Date:
2024-10-25 @ 8:05 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06568640
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-18
Brief Title:
Superselective Adrenal Arterial Embolization for Refractory Hypertension A Proof-of-Concept Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluation and Exploration of the Safety and Efficacy of Superselective Adrenal Arterial Embolization in Patients With Essential Refractory Hypertension A Proof-of-Concept Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SAAE-RH
Brief Summary:
The subjects of this study were patients with essential refractory hypertension The purpose of this study is to evaluate the safety and efficacy of superselective adrenal arterial embolization SAAE in patients with primary refractory hypertension and to explore the possibility of SAAE in patients with primary refractory hypertensionAfter the subject completes the SAAE an 8-week follow-up will be conducted to assess the safety and effectiveness of the SAAE
Detailed Description:
The subjects of this study were patients with essential refractory hypertension The study design was a single-center open-label self-controlled single-arm prospective study The purpose of this study is to evaluate the safety and efficacy of superselective adrenal arterial embolization SAAE in patients with primary refractory hypertension and to explore the possibility of SAAE in patients with primary refractory hypertensionAfter the subject completes the SAAE an 8-week follow-up will be conducted to assess the safety and effectiveness of the SAAE
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None